On Tuesday 27 April 2021 in St. Petersburg, Russian biotechnological company BioPalette launched the mass production of "MultiSCREEN," the world's first test system designed to simultaneously screen for the presence of such diseases as HIV, hepatitis B and C, and syphilis.
According to BioPalette head Vladimir Okrul, the company needed to invest 80 million rubles ($1 million) to begin mass production of the screening kit, and Russia's Industrial Development Fund has provided a preferential loan of 50.7 million rubles.
According to BioPalette development director Andrey Berezin, the firm has decided to create a combined test, as it now occupies about 7% of the market for diagnostics in the field of HIV tests, while the market for the "hospital four" -- that is, the most common tests: hepatitis B & C, syphilis, and HIV - is estimated at 6.7 billion rubles.
No comments:
Post a Comment